MMRF PRESS RELEASES
The Multiple Myeloma Research Foundation Congratulates and Supports Senator Kay Bailey Hutchinson for Her Commitment to Blood Disease Research and Education
March 24, 2004
The Multiple Myeloma Research Foundation (MMRF) is pleased to be a part of today's activities announcing funding for the Geraldine Ferraro Blood Cancer Education Program and to support Senator Kay Bailey Hutchison's efforts surrounding improved research and education funding for blood diseases.
The Geraldine Ferraro Blood Cancer Education Program was established on Blood Cancer Advocacy Day 2002 as part of The Hematological Cancer Research Investment and Education Act, which President Bush signed on May 14, 2002. The MMRF has worked closely with Senator Hutchison to fund this program, as it has for each Blood Cancer Advocacy Day, to advance public policy initiatives that accelerate and intensify efforts to bring new therapies and high quality care to patients everywhere with blood-related cancers.
Senator Hutchison, whose own brother suffers from multiple myeloma, has been working for several years to pass legislation that will increase medical research and education funding to help find a cure for fatal blood diseases such as multiple myeloma. Most recently, her efforts have secured $5 million to bring vital education services to blood cancer patients and their families.
"We want to commend Senator Hutchison for her years of dedication to make this funding a reality," says Kathy Giusti, president and founder of the MMRF. "As the leading private funding source for myeloma-specific research, the MMRF is grateful to Senator Hutchison for recognizing that deaths from blood-related cancers continue to increase, and this funding is crucial to saving thousands of lives."
There are approximately 45,000 people in the United States living with Multiple Myeloma and an estimated 14,600 new cases are diagnosed each year.
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 and is now the world's number-one private funder of myeloma-specific research, supporting innovative efforts in the most promising areas of cancer research. The MMRF has raised more than $50 million and has funded more than 45 research institutions around the globe, bringing scientific breakthroughs from the laboratory to the clinic and laying the groundwork for promising, new treatments. Ninety-three percent of MMRF funds are channeled directly into multiple myeloma research and related programming.
The MMRF is dedicated to building interdisciplinary collaborations among researchers, pharmaceutical companies and biotech firms, and the National Cancer Institute to improve therapeutic treatments for multiple myeloma patients. To learn more about the MMRF and its programs, call 203-972-1250 or visit www.themmrf.org.
For information, contact:
Anne Quinn Young, MMRF, 203-652-0212, email@example.com